Not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.
PSC Trial Watch
UCRecruiting

ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea

Early Phase 1 · Testing mesalazine, ND-12 and ND-12/H-6 · 1 site · The Second Hospital of Nanjing Medical University

Official record & contacts on ClinicalTrials.gov ↗

In plain English

What this trial is testing

This study is testing mesalazine (a drug), ND-12 (a drug) and ND-12/H-6 (a drug) as a possible treatment. Condition(s) listed: Diarrhea Chronic and UC - Ulcerative Colitis.

Participants are assigned to groups by chance (randomized).

It is blinded: participants and the study team do not know who receives what.

Early Phase 1 studies are very small first studies in people, mainly checking safety and how the body handles a treatment.

Who can join

Some of the main requirements, copied from the record:

Plus 1 more requirement(s). There are also 21 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.

What's involved

Main thing being measured

In the researchers’ words

This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea

This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.

Questions to ask your doctor and the trial team

Official details

StatusRecruiting
PhaseEarly Phase 1
Study typeInterventional
ConditionsDiarrhea Chronic; UC - Ulcerative Colitis
Lead sponsorThe Second Hospital of Nanjing Medical University
CollaboratorsNeurodawn Pharmaceutical Co., Ltd.
Enrollment36 (estimated)
Start date2026-07-20
Primary completion (est.)2028-08-31
First posted2026-08-17
Last updated2026-08-17
Official titleA Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea
ClinicalTrials.gov IDNCT07767370

Interventions

Full eligibility criteria (from the record)
Inclusion Criteria:

1. Subjects aged 18-75 years (inclusive), of any gender.
2. Meet any one of the following conditions:

1) Previously diagnosed ulcerative colitis, currently in the active phase; 2) Diagnosis of chronic diarrhoea: stool frequency ≥3 times per day or markedly higher than the subject's usual baseline; disease duration >4 weeks; recurrent diarrhoea with an interval of 2-4 weeks between episodes; loose stools (Bristol Stool Form Scale type 5, 6, or 7).

3\. Faecal calprotectin >150 μg/g. 4.The subject or their legal representative provides informed consent by voluntarily signing the informed consent form, fully understands the study objectives, maintains effective communication with investigators, and is capable of understanding and complying with all requirements specified in this study protocol.

Exclusion Criteria:

Exclusion criteria related to chronic diarrhoea

1. Presence of any of the following symptoms:

   1. Fever ≥37.5°C;
   2. Moderate-to-severe dehydration requiring intravenous fluid replacement;
   3. Recurrent vomiting.
2. Diarrhoea caused by enteric pathogens (e.g., Clostridioides difficile, Salmonella typhi, etc.).
3. Underlying diseases that may trigger diarrhoea, including hyperthyroidism, gastrointestinal autonomic nervous dysfunction, gastrointestinal malignancy, Crohn's disease, history of colectomy (appendectomy, haemorrhoid surgery and fistula-in-ano surgery excluded), history of small-bowel resection (>20 cm of resected intestinal segment), etc.

   Drug-related exclusion criteria
4. Suspected drug-induced diarrhoea (e.g., long-term use of laxatives, antibiotics, chemotherapeutic agents, etc.) where discontinuation of the offending drug is not feasible.
5. History of allergy to any component of mesalazine capsules, ND-12 capsules or H-6 capsules.
6. Anticipated need for prohibited medications during the study (e.g. antibiotics, antidiarrhoeals, antiemetics, antispasmodics, etc.).
7. Use of any investigational drug within 30 days prior to enrolment into this study.

   Other gastrointestinal exclusion criteria
8. History of gastrectomy or vagotomy.
9. Known malabsorptive disorders include coeliac disease.
10. Known lactose intolerance.
11. Any suspected condition requiring abdominal surgery. Other exclusion criteria
12. Confirmed human immunodeficiency virus (HIV) positive status, known or suspected immunosuppression.
13. Known severe hepatic or renal insufficiency.
14. Past or current history of alcohol abuse and/or known substance abuse (cocaine, heroin, cannabis, etc.).
15. Any psychiatric condition impairing the subject's ability to understand the nature, scope and potential consequences of the study, and/or documented evidence of non-cooperation.
16. Pregnant or lactating women.

Locations (1)

SiteCityCountrySite status
The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, JiangsuChinaRecruiting

For contacts at each site, use the official record.

Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.